Clinical Trial Update: A Phase I Study to Investigate the Tolerability and Safety of ONO-4685 Given as Monotherapy in T Cell Lymphoma and CLL/SLL [Phase 1]

View source ↗

Summary

Phase I study of ONO-4685 as monotherapy to evaluate tolerability and safety in relapsed or refractory T cell lymphoma and chronic lymphocytic leukemia/small ly…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Or Refractory Cell Lymphoma
• Small Lymphocytic Lymphoma

Drugs mentioned

• ONO-4685

Snippet

Sponsor: Ono Pharmaceutical Co., Ltd. | Conditions: Relapsed or Refractory T Cell Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Phase 1 | Status: RECRUITING